Apollomics (APLM) Common Equity (2020 - 2025)

Apollomics (APLM) posted quarterly Common Equity of $3.2 million for Q4 2025, down 94.28% quarter-over-quarter from $55.7 million in Q2 2023.

Apollomics (APLM) Common Equity (2020 - 2025) Analysis & Trends

Apollomics (APLM) has reported Common Equity for 5 consecutive years, with $3.2 million the latest figure, recorded in Q4 2025.

In Q4 2025, Common Equity changed N/A year-over-year to $3.2 million; the TTM figure through Dec 2025 stood at $3.2 million (changed N/A YoY), while the FY2025 annual figure was $3.2 million, changed N/A from the prior year.
Common Equity retreated to $3.2 million in Q4 2025 per APLM's latest filing, from $55.7 million in the prior quarter.
Across five years, Common Equity topped out at $55.7 million in Q2 2023 and bottomed at -$448.1 million in Q4 2022.
Historically, Common Equity has averaged -$162.9 million across 4 years, with a median of -$212.5 million in 2022.
Annual changes were most pronounced in 2022 — Common Equity plunged 110.52% — and 2023, when it surged 126.21%.
Apollomics' Common Equity stood at -$212.9 million in 2021, then slumped by 110.52% to -$448.1 million in 2022, then soared by 112.43% to $55.7 million in 2023, then slumped by 94.28% to $3.2 million in 2025.
Business Quant data shows APLM's Common Equity at $3.2 million in Q4 2025, $55.7 million in Q2 2023, and -$448.1 million in Q4 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Common Equity (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	20.25 Bn
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	31.71 Bn
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	-
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	6.76 Bn
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	5.17 Bn
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	1.35 Bn
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	757.49 Mn
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	9.79 Bn
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	22.38 Bn
10	Apollomics	34.08 Mn	30.81 Mn	-	-275,000.00

Download Data